BiotechTube
Clarus Biologics

Clarus Biologics

Cambridge, United States· Est.
clarusbiologics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $60M

Overview

Clarus Biologics is a private, pre-clinical stage biotech focused on developing a novel VLP-based adjuvant platform, CBI-3A, to address key challenges in modern vaccinology. The company's technology aims to elicit broad adaptive and innate immune responses, offers antigen-sparing capabilities, and has demonstrated preclinical proof-of-concept across multiple species and antigens. Led by a team of industry veterans, Clarus is positioning its platform for partnerships and licensing to accelerate the development of more effective prophylactic and therapeutic vaccines.

Infectious Diseases

Technology Platform

Novel Virus-Like Particle (VLP) adjuvant platform (CBI-3A) designed to stimulate broad innate and adaptive immune responses, including antibody, T-cell, and mucosal immunity, with antigen-sparing capabilities.

Funding History

2
Total raised:$60M
Series A$45M
Seed$15M

Opportunities

The global need for novel, more effective vaccine adjuvants is strong, driven by challenges in immunizing vulnerable populations and combating complex pathogens.
Clarus's versatile VLP platform, with its antigen-sparing and mucosal immunity features, could address key industry pain points and attract partnership deals from larger vaccine developers seeking to enhance their pipelines.

Risk Factors

The company faces high technical risk in translating preclinical results to human efficacy and safety.
As a single-asset, pre-revenue private company, it is vulnerable to funding constraints and intense competition from established adjuvant manufacturers and numerous other biotech platforms.
Its partnership-dependent business model carries execution risk.

Competitive Landscape

Clarus competes in the vaccine adjuvant market against large players like GSK (with its AS adjuvant series) and Dynavax (CpG 1018), as well as numerous biotech firms developing novel adjuvants (e.g., based on saponins, emulsions, TLR agonists). Differentiation will rely on demonstrating superior breadth of immune response, mucosal immunity induction, and antigen-sparing in clinical settings.

More companies in Biologics / Biosimilars →More companies in United States →